Compass Therapeutics, Inc. (NASDAQ:CMPX) Short Interest Update

Compass Therapeutics, Inc. (NASDAQ:CMPX) saw a significant increase in short interest in March. As of March 15th, there was short interest totalling 4,610,000 shares, an increase of 24.6% from the February 28th total of 3,700,000 shares. Based on an average trading volume of 1,440,000 shares, the short-interest ratio is currently 3.2 days. Approximately 5.7% of the company’s stock are sold short.

Analyst Ratings Changes

CMPX has been the topic of several recent research reports. D. Boral Capital reaffirmed a “buy” rating and issued a $32.00 price target on shares of Compass Therapeutics in a research report on Tuesday. Jefferies Financial Group raised their target price on Compass Therapeutics from $7.00 to $8.00 and gave the company a “buy” rating in a report on Monday, February 10th. HC Wainwright reaffirmed a “buy” rating and set a $10.00 target price on shares of Compass Therapeutics in a research report on Wednesday, January 8th. Leerink Partners raised Compass Therapeutics from a “market perform” rating to an “outperform” rating and increased their price target for the company from $4.00 to $6.00 in a research report on Wednesday. Finally, Wedbush reaffirmed an “outperform” rating and set a $8.00 price objective on shares of Compass Therapeutics in a report on Tuesday. One investment analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $11.63.

Institutional Investors Weigh In On Compass Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Intech Investment Management LLC purchased a new position in shares of Compass Therapeutics in the third quarter worth about $30,000. The Manufacturers Life Insurance Company bought a new position in shares of Compass Therapeutics in the third quarter worth $79,000. XTX Topco Ltd purchased a new position in Compass Therapeutics during the 3rd quarter valued at about $37,000. Barclays PLC grew its stake in Compass Therapeutics by 195.4% during the third quarter. Barclays PLC now owns 170,245 shares of the company’s stock valued at $314,000 after acquiring an additional 112,614 shares in the last quarter. Finally, Geode Capital Management LLC increased its holdings in shares of Compass Therapeutics by 0.8% in the third quarter. Geode Capital Management LLC now owns 2,309,778 shares of the company’s stock worth $4,251,000 after purchasing an additional 19,095 shares during the period. 68.43% of the stock is currently owned by institutional investors.

Compass Therapeutics Stock Performance

NASDAQ:CMPX traded down $0.17 during trading on Wednesday, reaching $2.08. The company’s stock had a trading volume of 2,467,876 shares, compared to its average volume of 1,929,862. Compass Therapeutics has a 12 month low of $0.76 and a 12 month high of $4.08. The firm has a market cap of $286.94 million, a price-to-earnings ratio of -5.61 and a beta of 1.19. The firm has a 50 day moving average of $2.83 and a 200-day moving average of $2.11.

Compass Therapeutics (NASDAQ:CMPX) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.01). Equities research analysts forecast that Compass Therapeutics will post -0.36 earnings per share for the current fiscal year.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.